Immunotherapies for hepatocellular carcinoma
The DOI matches its Crossref record; 216 of the 217 references it cites were found in a registry or an index.
Abstract
Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death and its incidence is increasing globally. Around 50% of patients with HCC receive systemic therapies, traditionally sorafenib or lenvatinib in the first line and regorafenib, cabozantinib or ramucirumab in the second line. In the past 5 years, immune-checkpoint inhibitors have revolutionized the management of HCC. The combination of atezolizumab and bevacizumab has been shown to improve overall survival relative to sorafenib, resulting in FDA approval of this regimen. More recently, durvalumab plus tremelimumab yielded superior overall survival versus sorafenib and atezolizumab plus cabozantinib yielded superior progression-free survival. In addition, pembrolizumab monotherapy and the combination of nivolumab plus ipilimumab have received FDA Accelerated Approval in the second-line setting based on early efficacy data. Despite these major advances, the molecular underpinnings governing immune responses and evasion remain unclear. The immune microenvironment has crucial roles in the development and progression of HCC and distinct aetiology-dependent immune features have been defined. Inflamed and non-inflamed classes of HCC and genomic signatures have been associated with response to immune-checkpoint inhibitors, yet no validated biomarker is available to guide clinical decision-making. This Review provides information on the immune microenvironments underlying t…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Over the past two decades, the development of effective systemic therapies has substantially improved the outcomes of patients with advanced-stage HCC2–6.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [5]
In the citing paper
“In the liver, the immune microenvironment primarily comprises immunosuppressive cells and signals that create a tolerogenic niche1,5,59.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [5]
In the citing paper
“Key cells involved in immune evasion in HCC include tissue-resident macrophages (Kupffer cells), regulatory T (Treg) cells, monocyte-derived macrophages and immature granulocytic cells often collectively referred to as myeloid-derived suppressor cells (MDSCs)5 (Fig. 1).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [5]
In the citing paper
“Currently, the main immunotherapeutic approach for patients with HCC — regardless of tumour stage — involves restoring antitumour immunity with ICIs, which are monoclonal antibodies that block inhibitory checkpoints or their ligands5.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [5]
In the citing paper
“For patients with advanced-stage HCC, the current availability of ~10 systemic regimens1,2,5,35,40 has resulted in a shift from median OS durations of 6–8 months to 19–20 months after first-line treatment and 10–14 months after second-line treatment (Fig. 4a).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [5]
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationLlovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationCancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
AASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2018) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,070
Self-citationBrahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Self-citationAdverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.035 · Cited by 2,152
(1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-5-642_1 · Cited by 2,081
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Thermal ablation of tumours: biological mechanisms and advances in therapy
Chu, K. F., & Dupuy, D. E. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3672 · Cited by 1,988
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Gao, B., & Bataller, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.002 · Cited by 1,963
Molecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938 · cited 1×
“Kupffer cells, which constitute up to 90% of liver macrophages, and other TAMs can contribute to hepatocarcinogenesis and immune evasion through several mechanisms, including (1) secretion of IL-10 and other immunosuppressive cytokines in response to antigens and damageassociated or microbiomederived signals; (2) expr…”
BackgroundSelf-citationFinn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789
Self-citationT-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
Zhang, Q., He, Y., Luo, N., Patel, S. J., Han, Y., Gao, R., Modak, M., Carotta, S., Haslinger, C., Kind, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.003 · Cited by 1,624
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Llovet, J. M., Ducreux, M. P., Lencioni, R. A., Bisceglie, A. M. D., Dufour, J., Greten, T. F., Raymond, É., Roskams, T., Mazzaferro, V., Bruix, J., et al. (2012) · Cited by 1,488
Self-citationTumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Davoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,360
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.007 · Cited by 1,346
Advances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03362-0 · Cited by 1,294
Self-citationYau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4564 · Cited by 1,273
Finn, R. S., Ikeda, M., Zhu, A. X., Sung, M. W., Baron, A. D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00808 · Cited by 1,167
Self-citationYokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161
Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00252-7 · Cited by 1,124
The immunology of hepatocellular carcinoma
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E., & Heikenwalder, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0044-z · Cited by 1,076
Self-citationLocoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., & Lencioni, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00395-0 · Cited by 1,044 · cited 2×
“Kupffer cells, which constitute up to 90% of liver macrophages, and other TAMs can contribute to hepatocarcinogenesis and immune evasion through several mechanisms, including (1) secretion of IL-10 and other immunosuppressive cytokines in response to antigens and damageassociated or microbiomederived signals; (2) expr…”
BackgroundSelf-citationLiu, D., Schilling, B., Liu, D., Sucker, A., Livingstone, E., Jerby-Arnon, L., Zimmer, L., Gutzmer, R., Satzger, I., Loquai, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0654-5 · Cited by 1,039
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
Yu, J., Green, M. D., Li, S., Sun, Y., Journey, S. N., Choi, J. E., Rizvi, S. M., Qin, A., Waninger, J. J., Lang, X., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-1131-x · Cited by 1,001
Classification and characterization of microsatellite instability across 18 cancer types
Hause, R. J., Pritchard, C. C., Shendure, J., & Salipante, S. J. (2016) · Nature Medicine · doi:10.1038/nm.4191 · Cited by 991
Sangro, B., Gomez-Martin, C., de la Mata, M., Iñarrairaegui, M., Garralda, E., Barrera, P., Riezu-Boj, J. I., Larrea, E., Alfaro, C., Sarobe, P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.022 · Cited by 980
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976
Self-citationPeggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Gay, C. M., Stewart, C. A., Park, E. M., Diao, L., Groves, S. M., Heeke, S., Nabet, B. Y., Fujimoto, J., Solis, L. M., Lu, W., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.014 · Cited by 962
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
Chinese Human Proteome Project (CNHPP) Consortium, Jiang, Y., Sun, A., Zhao, Y., Ying, W., Sun, H., Yang, X., Xing, B., Sun, W., Ren, L., et al. (2019) · Nature · doi:10.1038/s41586-019-0987-8 · Cited by 947
Neoantigen-directed immune escape in lung cancer evolution
The TRACERx consortium, Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., Lund, T., Tanić, M., Reading, J. L., et al. (2019) · Nature · doi:10.1038/s41586-019-1032-7 · Cited by 946
Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912
Self-citationSingle-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma
Sun, Y., Wu, L., Zhong, Y., Zhou, K., Hou, Y., Wang, Z., Zhang, Z., Xie, J., Wang, C., Chen, D., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.041 · Cited by 895
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0577 · Cited by 894
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Litchfield, K., Reading, J. L., Puttick, C., Thakkar, K., Abbosh, C., Bentham, R., Watkins, T. B. K., Rosenthal, R., Biswas, D., Rowan, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.002 · Cited by 893
Takayama, T., Sekine, T., Makuuchi, M., Yamasaki, S., Kosuge, T., Yamamoto, J., Shimada, K., Sakamoto, M., Hirohashi, S., Ohashi, Y., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02654-4 · Cited by 847
Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer
Ma, L., Hernandez, M. O., Zhao, Y., Mehta, M., Tran, B., Kelly, M., Rae, Z., Hernandez, J. M., Davis, J. L., Martin, S. P., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.007 · Cited by 844
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Duffy, A. G., Ulahannan, S. V., Makorova-Rusher, O., Rahma, O., Wedemeyer, H., Pratt, D., Davis, J. L., Hughes, M. S., Heller, T., ElGindi, M., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.10.029 · Cited by 819
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., et al. (2020) · Liver Cancer · doi:10.1159/000509424 · Cited by 800
Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793
NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
Ma, C., Kesarwala, A. H., Eggert, T., Medina-Echeverz, J., Kleiner, D. E., Jin, P., Stroncek, D. F., Terabe, M., Kapoor, V., ElGindi, M., et al. (2016) · Nature · doi:10.1038/nature16969 · Cited by 766
Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
Self-citationYau, T., Tang, V. Y. F., Yao, T.-J., Fan, S.-T., Lo, C.-M., & Poon, R. T. P. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.032 · Cited by 698
Wolf, M. J., Adili, A., Piotrowitz, K., Abdullah, Z., Boege, Y., Stemmer, K., Ringelhan, M., Simonavicius, N., Egger, M., Wohlleber, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.003 · Cited by 678
Self-citationPonziani, F. R., Bhoori, S., Castelli, C., Putignani, L., Rivoltini, L., Del Chierico, F., Sanguinetti, M., Morelli, D., Paroni Sterbini, F., Petito, V., et al. (2019) · Hepatology · doi:10.1002/hep.30036 · Cited by 654
Self-citationParlesak, A., Schäfer, C., Schütz, T., Bode, J. C., & Bode, C. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80242-1 · Cited by 647
Yau, T., Park, J. W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Han, K.-H., Harding, J. J., Merle, P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.029 · Cited by 647
Self-citationTopalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Sosman, J. A., Atkins, M. B., Leming, P. D., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2187 · Cited by 619
Harding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M., Shia, J., Hechtman, J. F., Kundra, R., El Dika, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2293 · Cited by 602
Qin, S., Ren, Z., Meng, Z., Chen, Z., Chai, X., Xiong, J., Bai, Y., Yang, L., Zhu, H., Fang, W., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30011-5 · Cited by 602
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Yearley, J. H., Gibson, C., Yu, N., Moon, C., Murphy, E., Juco, J., Lunceford, J., Cheng, J., Chow, L. Q. M., Seiwert, T. Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1761 · Cited by 594
Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity
Shalapour, S., Lin, X.-J., Bastian, I. N., Brain, J., Burt, A. D., Aksenov, A. A., Vrbanac, A. F., Li, W., Perkins, A., Matsutani, T., et al. (2017) · Nature · doi:10.1038/nature24302 · Cited by 589
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
Dolladille, C., Ederhy, S., Sassier, M., Cautela, J., Thuny, F., Cohen, A. A., Fedrizzi, S., Chrétien, B., Da-Silva, A., Plane, A.-F., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0726 · Cited by 587
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beg, M. S., Brower, S. T., Gade, T. P., Goff, L., Gupta, S., Guy, J., Harris, W. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02672 · Cited by 570
Self-citationXu, J., Shen, J., Gu, S., Zhang, Y., Wu, L., Wu, J., Shao, G., Zhang, Y., Xu, L., Yin, T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2571 · Cited by 565
An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection
Cabrera, R., Tu, Z., Xu, Y., Firpi, R. J., Rosen, H. R., Liu, C., & Nelson, D. R. (2004) · Hepatology · doi:10.1002/hep.20454 · Cited by 562
Shen, J., Ju, Z., Zhao, W., Wang, L., Peng, Y., Ge, Z., Nagel, Z. D., Zou, J., Wang, C., Kapoor, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0012-z · Cited by 562
Lee, M. S., Ryoo, B.-Y., Hsu, C.-H., Numata, K., Stein, S., Verret, W., Hack, S. P., Spahn, J., Liu, B., Abdullah, H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30156-x · Cited by 562
Zheng, Y., Wang, T., Tu, X., Huang, Y., Zhang, H., Tan, D., Jiang, W., Cai, S., Zhao, P., Song, R., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0650-9 · Cited by 550
Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH
Dudek, M., Pfister, D., Donakonda, S., Filpe, P., Schneider, A., Laschinger, M., Hartmann, D., Hüser, N., Meiser, P., Bayerl, F., et al. (2021) · Nature · doi:10.1038/s41586-021-03233-8 · Cited by 518
Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
Lee, J. H., Lee, J.-H., Lim, Y.-S., Yeon, J. E., Song, T.-J., Yu, S. J., Gwak, G.-Y., Kim, K. M., Kim, Y. J., Lee, J. W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.055 · Cited by 503
Calderaro, J., Petitprez, F., Becht, E., Laurent, A., Hirsch, T. Z., Rousseau, B., Luciani, A., Amaddeo, G., Derman, J., Charpy, C., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.003 · Cited by 479
Role of PD-1 during effector CD8 T cell differentiation
Ahn, E., Araki, K., Hashimoto, M., Li, W., Riley, J. L., Cheung, J., Sharpe, A. H., Freeman, G. J., Irving, B. A., & Ahmed, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718217115 · Cited by 474
Vogel, A., Martinelli, E., Vogel, A., Cervantes, A., Chau, I., Daniele, B., Llovet, J. M., Meyer, T., Nault, J.-C., Neumann, U., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.014 · Cited by 458
Self-citationMason, W. S., Gill, U. S., Litwin, S., Zhou, Y., Peri, S., Pop, O., Hong, M. L. W., Naik, S., Quaglia, A., Bertoletti, A., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.07.012 · Cited by 449
Genomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448
Kelley, R. K., Sangro, B., Harris, W., Ikeda, M., Okusaka, T., Kang, Y.-K., Qin, S., Tai, D. W.-M., Lim, H. Y., Yau, T., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03555 · Cited by 444
Calderaro, J., Rousseau, B., Amaddeo, G., Mercey, M., Charpy, C., Costentin, C., Luciani, A., Zafrani, E., Laurent, A., Azoulay, D., et al. (2016) · Hepatology · doi:10.1002/hep.28710 · Cited by 440
Finkin, S., Yuan, D., Stein, I., Taniguchi, K., Weber, A., Unger, K., Browning, J. L., Goossens, N., Nakagawa, S., Gunasekaran, G., et al. (2015) · Nature Immunology · doi:10.1038/ni.3290 · Cited by 433
Self-citationTrial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413
Self-citationQin, S., Bi, F., Gu, S., Bai, Y., Chen, Z., Wang, Z., Ying, J., Lu, Y., Meng, Z., Pan, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00163 · Cited by 409
Sangro, B., Melero, I., Wadhawan, S., Finn, R. S., Abou-Alfa, G. K., Cheng, A.-L., Yau, T., Furuse, J., Park, J.-W., Boyd, Z., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.026 · Cited by 407
Self-citationGomes, A. L., Teijeiro, A., Burén, S., Tummala, K. S., Yilmaz, M., Waisman, A., Theurillat, J.-P., Perna, C., & Djouder, N. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.020 · Cited by 401
Liver inflammation abrogates immunological tolerance induced by Kupffer cells
Heymann, F., Peusquens, J., Ludwig‐Portugall, I., Kohlhepp, M., Ergen, C., Niemietz, P., Martin, C., van Rooijen, N., Ochando, J. C., Randolph, G. J., et al. (2015) · Hepatology · doi:10.1002/hep.27793 · Cited by 398
Malehmir, M., Pfister, D., Gallage, S., Szydlowska, M., Inverso, D., Kotsiliti, E., Leone, V., Peiseler, M., Surewaard, B. G. J., Rath, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0379-5 · Cited by 398
Self-citationHuinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 395
Systemic treatment of hepatocellular carcinoma: An EASL position paper
Bruix, J., Chan, S. L., Galle, P. R., Rimassa, L., & Sangro, B. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.004 · Cited by 380
Shi, D., Shi, Y., Kaseb, A. O., Qi, X., Zhang, Y., Chi, J., Lu, Q., Gao, H., Jiang, H., Wang, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3259 · Cited by 378
Hodi, F. S., Ballinger, M., Lyons, B., Soria, J.-C., Nishino, M., Tabernero, J., Powles, T., Smith, D., Hoos, A., McKenna, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1644 · Cited by 366
Gut microbiome in HCC – Mechanisms, diagnosis and therapy
Schwabe, R. F., & Greten, T. F. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.016 · Cited by 363
Temporal Analysis of Early Immune Responses in Patients With Acute Hepatitis B Virus Infection
Dunn, C., Peppa, D., Khanna, P., Nebbia, G., Jones, M., Brendish, N., Lascar, R. M., Brown, D., Gilson, R. J., Tedder, R. J., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.054 · Cited by 362
Self-citationHepatocellular carcinoma in the setting of alcohol-related liver disease
Ganne-Carrié, N., & Nahon, P. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.008 · Cited by 360
Ho, W. J., Zhu, Q., Durham, J., Popovic, A., Xavier, S., Leatherman, J., Mohan, A., Mo, G., Zhang, S., Gross, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00234-4 · Cited by 360
Lim, C. J., Lee, Y. H., Pan, L., Lai, L., Chua, C., Wasser, M., Lim, T. K. H., Yeong, J., Toh, H. C., Lee, S. Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316510 · Cited by 357
Zhou, S.-L., Dai, Z., Zhou, Z.-J., Wang, X.-Y., Yang, G.-H., Wang, Z., Huang, X.-W., Fan, J., & Zhou, J. (2012) · Hepatology · doi:10.1002/hep.25907 · Cited by 356
Flecken, T., Schmidt, N., Hild, S., Gostick, E., Drognitz, O., Zeiser, R., Schemmer, P., Bruns, H., Eiermann, T., Price, D. A., et al. (2014) · Hepatology · doi:10.1002/hep.26731 · Cited by 351
Duan, J., Cui, L., Zhao, X., Bai, H., Cai, S., Wang, G., Zhao, Z., Zhao, J., Chen, S., Song, J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5367 · Cited by 349
Maker, A. V., Attia, P., & Rosenberg, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7746 · Cited by 343
Mazzaferro, V., Citterio, D., Bhoori, S., Bongini, M., Miceli, R., De Carlis, L., Colledan, M., Salizzoni, M., Romagnoli, R., Antonelli, B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30224-2 · Cited by 341
Self-citationIL-10–Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection
Das, A., Ellis, G., Pallant, C., Lopes, A. R., Khanna, P., Peppa, D., Chen, A., Blair, P., Dusheiko, G., Gill, U., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103139 · Cited by 339
Self-citationJob, S., Rapoud, D., Dos Santos, A., Gonzalez, P., Desterke, C., Pascal, G., Elarouci, N., Ayadi, M., Adam, R., Azoulay, D., et al. (2020) · Hepatology · doi:10.1002/hep.31092 · Cited by 322
Tilg, H., Moschen, A. R., & Szabo, G. (2016) · Hepatology · doi:10.1002/hep.28456 · Cited by 319
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V. V., Merle, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.267 · Cited by 319
Self-citationSitia, G., Aiolfi, R., Di Lucia, P., Mainetti, M., Fiocchi, A., Mingozzi, F., Esposito, A., Ruggeri, Z. M., Chisari, F. V., Iannacone, M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209182109 · Cited by 317
Innate and adaptive immune responses in HCV infections
Heim, M. H., & Thimme, R. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.06.035 · Cited by 305
Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality
Simon, T. G., Duberg, A.-S., Aleman, S., Chung, R. T., Chan, A. T., & Ludvigsson, J. F. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912035 · Cited by 304
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Montal, R., Sia, D., Montironi, C., Leow, W. Q., Esteban-Fabró, R., Pinyol, R., Torres-Martin, M., Bassaganyas, L., Moeini, A., Peix, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.008 · Cited by 301
Self-citationDiagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Sangro, B., Chan, S. L., Meyer, T., Reig, M., El-Khoueiry, A., & Galle, P. R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.021 · Cited by 293
Palmer, D. H., Midgley, R. S., Mirza, N., Torr, E. E., Ahmed, F., Steele, J. C., Steven, N. M., Kerr, D. J., Young, L. S., & Adams, D. H. (2009) · Hepatology · doi:10.1002/hep.22626 · Cited by 286
Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells
Pallett, L. J., Gill, U. S., Quaglia, A., Sinclair, L. V., Jover-Cobos, M., Schurich, A., Singh, K. P., Thomas, N., Das, A., Chen, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3856 · Cited by 279
Self-citationTissue-resident memory T cells at the center of immunity to solid tumors
Amsen, D., van Gisbergen, K. P. J. M., Hombrink, P., & van Lier, R. A. W. (2018) · Nature Immunology · doi:10.1038/s41590-018-0114-2 · Cited by 278
Chen, Y.-P., Wang, Y.-Q., Lv, J.-W., Li, Y.-Q., Chua, M. L. K., Le, Q.-T., Lee, N., Colevas, A. D., Seiwert, T., Hayes, D. N., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy470 · Cited by 275
Kalathil, S., Lugade, A. A., Miller, A., Iyer, R., & Thanavala, Y. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3381 · Cited by 271
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., Stumpf, C. R., Xue, L., Devericks, E., So, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0321-2 · Cited by 261
Haber, P. K., Puigvehí, M., Castet, F., Lourdusamy, V., Montal, R., Tabrizian, P., Buckstein, M., Kim, E., Villanueva, A., Schwartz, M., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.008 · Cited by 248
Self-citationChew, V., Lee, Y. H., Pan, L., Nasir, N. J. M., Lim, C. J., Chua, C., Lai, L., Hazirah, S. N., Lim, T. K. H., Goh, B. K. P., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315485 · Cited by 235
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
Llovet, J. M., Montal, R., & Villanueva, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.028 · Cited by 233
Self-citationDong, L.-Q., Peng, L.-H., Ma, L.-J., Liu, D.-B., Zhang, S., Luo, S.-Z., Rao, J.-H., Zhu, H.-W., Yang, S.-X., Xi, S.-J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.12.014 · Cited by 232
Kudo, M., Matilla, A., Santoro, A., Melero, I., Gracián, A. C., Acosta-Rivera, M., Choo, S.-P., El-Khoueiry, A. B., Kuromatsu, R., El-Rayes, B., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.047 · Cited by 232
Han, Y., Chen, Z., Yang, Y., Jiang, Z., Gu, Y., Liu, Y., Lin, C., Pan, Z., Yu, Y., Jiang, M., et al. (2014) · Hepatology · doi:10.1002/hep.26694 · Cited by 226
Ma, H.-Y., Yamamoto, G., Xu, J., Liu, X., Karin, D., Kim, J. Y., Alexandrov, L. B., Koyama, Y., Nishio, T., Benner, C., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.12.016 · Cited by 216
Wieland, D., Kemming, J., Schuch, A., Emmerich, F., Knolle, P., Neumann-Haefelin, C., Held, W., Zehn, D., Hofmann, M., & Thimme, R. (2017) · Nature Communications · doi:10.1038/ncomms15050 · Cited by 213
Combined locoregional-immunotherapy for liver cancer
Greten, T. F., Mauda-Havakuk, M., Heinrich, B., Korangy, F., & Wood, B. J. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.027 · Cited by 212
Association Between Aspirin Use and Risk of Hepatocellular Carcinoma
Simon, T. G., Ma, Y., Ludvigsson, J. F., Chong, D. Q., Giovannucci, E. L., Fuchs, C. S., Meyerhardt, J. A., Corey, K. E., Chung, R. T., Zhang, X., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4154 · Cited by 211
Greten, T. F., Forner, A., Korangy, F., N'Kontchou, G., Barget, N., Ayuso, C., Ormandy, L. A., Manns, M. P., Beaugrand, M., & Bruix, J. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-209 · Cited by 208
Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A. W. H., Tong, J. H., Wong, J., Chong, C. C. N., Lai, P. B. S., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314032 · Cited by 201
Hou, J., Zhang, H., Sun, B., & Karin, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.014 · Cited by 193
Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Li, J., Wang, W., Zhang, Y., Cieślik, M., Guo, J., Tan, M., Green, M. D., Wang, W., Lin, H., Li, W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134402 · Cited by 191
Radiofrequency Thermal Ablation for Hepatocellular Carcinoma Stimulates Autologous NK-Cell Response
Zerbini, A., Pilli, M., Laccabue, D., Pelosi, G., Molinari, A., Negri, E., Cerioni, S., Fagnoni, F., Soliani, P., Ferrari, C., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.051 · Cited by 188
Preferential loss of IL‐2–secreting CD4+ T helper cells in chronic HCV infection†
Semmo, N., Day, C. L., Ward, S. M., Lucas, M., Harcourt, G., Loughry, A., & Klenerman, P. (2005) · Hepatology · doi:10.1002/hep.20669 · Cited by 186
Horwitz, E., Stein, I., Andreozzi, M., Nemeth, J., Shoham, A., Pappo, O., Schweitzer, N., Tornillo, L., Kanarek, N., Quagliata, L., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0782 · Cited by 185
Self-citationHyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
Kim, C. G., Kim, C., Yoon, S. E., Kim, K. H., Choi, S. J., Kang, B., Kim, H. R., Park, S.-H., Shin, E.-C., Kim, Y.-Y., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.010 · Cited by 185
Dai, H., Tong, C., Shi, D., Chen, M., Guo, Y., Chen, D., Han, X., Wang, H., Wang, Y., & Shen, P. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1846926 · Cited by 179
Song, G., Shi, Y., Zhang, M., Goswami, S., Afridi, S., Meng, L., Ma, J., Chen, Y., Lin, Y., Zhang, J., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-00214-5 · Cited by 175
Pembrolizumab for Microsatellite-Instability–High Advanced Colorectal Cancer
Ilson, D. H. (2020) · Journal watch · doi:10.1056/nejm-jw.na52865 · Cited by 170
Nordness, M. F., Hamel, S., Godfrey, C. M., Shi, C., Johnson, D. B., Goff, L. W., O’Dell, H., Perri, R. E., & Alexopoulos, S. P. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15617 · Cited by 169
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Anagnostou, V., Yarchoan, M., Hansen, A. R., Wang, H., Verde, F., Sharon, E., Collyar, D., Chow, L. Q. M., & Forde, P. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3065 · Cited by 166
New predictors for immunotherapy responses sharpen our view of the tumour microenvironment
Bruno, T. C. (2020) · Nature · doi:10.1038/d41586-019-03943-0 · Cited by 165
Agdashian, D., ElGindi, M., Xie, C., Sandhu, M., Pratt, D. W., Kleiner, D. E., Figg, W. D., Rytlewski, J. A., Sanders, C. M., Yusko, E. C., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02299-8 · Cited by 163
Ang, C., Klempner, S. J., Ali, S. M., Madison, R., Ross, J. S., Severson, E. A., Fabrizio, D., Goodman, A., Kurzrock, R., Suh, J., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26998 · Cited by 163
Torrens, L., Montironi, C., Puigvehí, M., Mesropian, A., Leslie, J., Haber, P. K., Maeda, M., Balaseviciute, U., Willoughby, C. E., Abril‐Fornaguera, J., et al. (2021) · Hepatology · doi:10.1002/hep.32023 · Cited by 163
Self-citationBTN3A1 governs antitumor responses by coordinating αβ and γδ T cells
Payne, K. K., Mine, J. A., Biswas, S., Chaurio, R. A., Perales-Puchalt, A., Anadon, C. M., Costich, T. L., Harro, C. M., Walrath, J., Ming, Q., et al. (2020) · Science · doi:10.1126/science.aay2767 · Cited by 162
Shigeta, K., Matsui, A., Kikuchi, H., Klein, S., Mamessier, É., Chen, I. X., Aoki, S., Kitahara, S., Inoue, K., Shigeta, A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001435 · Cited by 157
Self-citationTan, A. T., Yang, N., Krishnamoorthy, T. L., Oei, V., Chua, A., Zhao, X., Tan, H. S., Chia, A., Bert, N. L., Low, D. H. P., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.251 · Cited by 152
Chronically inflamed livers up-regulate expression of inhibitory B7 family members #
Kassel, R., Cruise, M. W., Iezzoni, J. C., Taylor, N. A., Pruett, T. L., & Hahn, Y. S. (2009) · Hepatology · doi:10.1002/hep.23173 · Cited by 148
d’Izarny-Gargas, T., Dürrbach, A., & Zaidan, M. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15811 · Cited by 148
Liu, L., Zhang, Z., Zheng, B., Shi, Y., Duan, M., Ma, L., Wang, Z., Dong, L., Dong, P., Shi, J., et al. (2019) · Hepatology · doi:10.1002/hep.30134 · Cited by 144
von Felden, J., Craig, A. J., Garcia-Lezana, T., Labgaa, I., Haber, P. K., D’Avola, D., Asgharpour, A., Dieterich, D., Bonaccorso, A., Torres-Martin, M., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01519-1 · Cited by 136
Self-citationLongevity and replenishment of human liver-resident memory T cells and mononuclear phagocytes
Pallett, L. J., Burton, A. R., Amin, O. E., Rodriguez-Tajes, S., Patel, A. A., Zakeri, N., Jeffery-Smith, A., Swadling, L., Schmidt, N. M., Baiges, A., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200050 · Cited by 134
Self-citationMichler, T., Kosinska, A. D., Festag, J., Bunse, T., Su, J., Ringelhan, M., Imhof, H., Grimm, D., Steiger, K., Mogler, C., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.032 · Cited by 130
Ritchie, G., Gasper, H., Man, J., Lord, S., Marschner, I., Friedlander, M., & Lee, C. K. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5236 · Cited by 122
Abel, M., Sène, D., Pol, S., Bourlière, M., Poynard, T., Charlotte, F., Cacoub, P., & Caillat-Zucman, S. (2006) · Hepatology · doi:10.1002/hep.21438 · Cited by 117
Maini, M. K., & Pallett, L. J. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30007-4 · Cited by 113
Self-citationHepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip
Goto, K., Suarez, A. A. R., Wrensch, F., Baumert, T. F., & Lupberger, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093057 · Cited by 112
Pinato, D. J., Mauri, F. A., Spina, P., Cain, O., Siddique, A., Goldin, R., Victor, S., Pizio, C., Akarca, A. U., Boldorini, R. L., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0466-x · Cited by 111
Self-citationImmunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
Fessas, P., Possamai, L. A., Clark, J., Daniels, E., Gudd, C., Mullish, B. H., Alexander, J. L., & Pinato, D. J. (2020) · Immunology · doi:10.1111/imm.13141 · Cited by 105
Self-citationImmunotherapeutic strategies for hepatocellular carcinoma
Butterfield, L. H. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.038 · Cited by 103
Meng, W. S., Butterfield, L. H., Ribas, A., Dissette, V. B., Heller, J. B., Miranda, G. A., Glaspy, J. A., McBride, W. H., & Economou, J. S. (2001) · PubMed · Cited by 99
Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint
Schmidt, N. M., Wing, P. A. C., Diniz, M. O., Pallett, L. J., Swadling, L., Harris, J. M., Burton, A. R., Jeffery-Smith, A., Zakeri, N., Amin, O. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22967-7 · Cited by 98
Self-citationβ-Catenin–mediated immune evasion pathway frequently operates in primary cutaneous melanomas
Nsengimana, J., Laye, J., Filia, A., O’Shea, S., Muralidhar, S., Poźniak, J., Droop, A., Chan, M., Walker, C., Parkinson, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95351 · Cited by 96
Moeini, A., Torrecilla, S., Tovar, V., Montironi, C., Andreu-Oller, C., Peix, J., Higuera, M., Pfister, D., Ramadori, P., Pinyol, R., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.07.028 · Cited by 92
Self-citationSprinzl, M. F., Puschnik, A. S., Schlitter, A. M., Schad, A., Ackermann, K., Esposito, I., Lang, H., Galle, P. R., Weinmann, A., Heikenwälder, M. F., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.011 · Cited by 85
Pinato, D. J., Kaneko, T., Saeed, A., Pressiani, T., Kaseb, A. O., Wang, Y., Szafron, D., Jun, T. W., Dharmapuri, S., Naqash, A. R., et al. (2020) · Cancers · doi:10.3390/cancers12071862 · Cited by 83
Self-citationCadoux, M., Caruso, S., Pham, S., Gougèlet, A., Pophillat, C., Riou, R., Loesch, R., Colnot, S., Nguyễn, C. T., Caldéraro, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.017 · Cited by 81
Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies
Siu, L. L., Ivy, S. P., Dixon, E. L., Gravell, A. E., Reeves, S. A., & Rosner, G. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3079 · Cited by 80
Pinato, D. J., Cortellini, A., Sukumaran, A., Cole, T., Pai, M., Habib, N., Spalding, D., Sodergren, M. H., Martinez, M., Dhillon, T., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08033-x · Cited by 79
Self-citationEnrico, D. H., Paci, A., Chaput, N., Karamouza, E., & Besse, B. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2337 · Cited by 78
Modulation of Cytokine-Induced Eosinophil Infiltration by Phosphodiesterase Inhibitors
Lagente, V., Pruniaux, M., Junien, J., & Moodley, I. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.6.7539326 · Cited by 75
Xue, H., Lin, F., Tan, H., Zhu, Z.-Q., Zhang, Z.-Y., & Zhao, L. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154815 · Cited by 74
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma
Pinato, D. J., Fessas, P., Sapisochin, G., & Marron, T. U. (2021) · Hepatology · doi:10.1002/hep.31697 · Cited by 74
Self-citationButterfield, L. H., Ribas, A., Potter, D. M., & Economou, J. S. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0337-9 · Cited by 70
Kaseb, A. O., Vence, L., Blando, J., Yadav, S. S., Ikoma, N., Pestana, R. C., Vauthey, J. N., Allison, J. P., & Sharma, P. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0605 · Cited by 67
Pinato, D. J., Marron, T. U., Mishra-Kalyani, P. S., Gong, Y. U. T., Wei, G., Szafron, D., Sharon, E., Saeed, A., Jun, T. W., Dharmapuri, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.020 · Cited by 66
Self-citationGudd, C. L. C., Au, L., Triantafyllou, E., Shum, B., Liu, T., Nathwani, R., Kumar, N., Mukherjee, S., Dhar, A., Woollard, K. J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.008 · Cited by 64
Self-citationYan, G., Wang, X., Sun, C., Zheng, X., Wei, H., Tian, Z., & Sun, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-02887-7 · Cited by 60
Fessas, P., Kaseb, A., Wang, Y., Saeed, A., Szafron, D., Jun, T., Dharmapuri, S., Rafeh Naqash, A., Muzaffar, M., Navaid, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001033 · Cited by 60
Self-citationBassaganyas, L., Pinyol, R., Esteban-Fabró, R., Torrens, L., Torrecilla, S., Willoughby, C. E., Franch-Expósito, S., Vila-Casadesús, M., Salaverria, I., Montal, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1497 · Cited by 58
Self-citationEl-Khoueiry, A. B., Melero, I., Yau, T. C., Crocenzi, T. S., Kudo, M., Hsu, C., Choo, S., Trojan, J., Welling, T., Meyer, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.475 · Cited by 56
Sangro, B., Park, J., Finn, R. S., Cheng, A., Mathurin, P., Edeline, J., Kudo, M., Han, K., Harding, J. J., Merle, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.078 · Cited by 56
Self-citationImmunotherapy-induced endocrinopathies: assessment, management and monitoring
Nogueira, E. F., Newsom‐Davis, T., & Morganstein, D. L. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819896182 · Cited by 51
Wong, C. N., Fessas, P., Dominy, K., Mauri, F. A., Kaneko, T., Parcq, P. D., Khorashad, J. S., Toniutto, P., Goldin, R. D., Avellini, C., et al. (2020) · Liver International · doi:10.1111/liv.14706 · Cited by 49
Self-citationKurino, T., Matsuda, R., Terui, A., Suzuki, H. Y., Kokubo, T., Uehara, T., Arano, Y., Hisaka, A., & Hatakeyama, H. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000400 · Cited by 47
Hu, J., Chen, S., Wang, X., Lin, N., Yang, J., & Wu, S. (2019) · Cancer Management and Research · doi:10.2147/cmar.s227961 · Cited by 41
Pinato, D. J., Kaseb, A. O., Wang, Y., Saeed, A., Szafron, D., Jun, T. W., Dharmapuri, S., Naqash, A. R., Muzaffar, M., Navaid, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000726 · Cited by 38
Self-citationDucreux, M., Zhu, A. X., Cheng, A.-L., Galle, P. R., Ikeda, M., Nicholas, A., Verret, W., Li, L., Gaillard, V. E., Lencioni, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.4071 · Cited by 37
Self-citationInefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma
Tauber, C., Schultheiß, M., Luca, R. D., Buettner, N., Llewellyn‐Lacey, S., Emmerich, F., Zehe, S., Price, D. A., Neumann‐Haefelin, C., Schmitt-Graeff, A. H., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27146 · Cited by 36
Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.
Haber, P. K., Torres-Martin, M., Dufour, J.-F., Verslype, C., Marquardt, J., Galle, P. R., Vogel, A., Meyer, T., Labgaa, I., Roberts, L. R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.4100 · Cited by 34
Self-citation
Research works printed but not linked: 2
- Tabrizian, P. et al. A US multicenter analysis of 2529 HCC patients undergoing liver transplantation: 10‐year outcome assessing the role of down‐staging to within Milan criteria. Hepatology 70, 10A–11A (2019).
- AstraZeneca. Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial in 1st-line unresectable liver cancer. astrazeneca.com, https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-and-tremelimumab-improved-os-in-liver-cancer.html (15 October 2021).
Cited by
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
“ICIs have since revolutionized the management of advanced-stage HCC 233 .”
BackgroundSelf-citationEvolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
Self-citationMolecular pathogenesis and systemic therapies for hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Kelley, R. K., El-Khoueiry, A., Reeves, H. L., Wang, X. W., Gores, G. J., & Villanueva, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00357-2 · Cited by 498
Self-citationBiology and therapeutic targeting of vascular endothelial growth factor A
Pérez-Gutiérrez, L., & Ferrara, N. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00631-w · Cited by 484
“Nevertheless, bevacizumab and other anti-VEGF agents have proven their utility in multiple cancer types and, over the last few years, in combination with immune-checkpoint inhibitors, have advanced the treatment of difficult-to-treat malignancies 257–259 .”
BackgroundLlovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00469-2 · Cited by 469
Self-citation
Metadata
- Authors
- Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S.
- Affiliations
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Hospital Clínic de Barcelona (ES)
- University College London (GB)
- University of Milan (IT)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Hebrew University of Jerusalem (IL)
- Massachusetts General Hospital (US)
- University of California, Los Angeles (US)
- Corresponding author
- Llovet, Josep M.
- ORCID
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2021-11-11
- Volume
- 19
- Issue
- 3
- Pages
- 151-172
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W3212903603
- Cited by
- 1,843
- References
- 217
- Citations by year
- 2026: 306 · 2025: 406 · 2024: 498 · 2023: 428 · 2022: 204
- FWCI
- 37.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust (214191/Z/18/Z, PS3416)
- Cancer Research UK (26603, 26813, C57701/A26137)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK056621, R01DK128289)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- hepatocellular carcinoma, immune checkpoint inhibitors, tumor immune microenvironment, atezolizumab, bevacizumab, durvalumab, tremelimumab, pembrolizumab, nivolumab, ipilimumab, immune evasion, immune-related adverse events, immunotherapy resistance, first-line and second-line therapy, liver cancer
- MeSH terms
- Sorafenib, Immune Checkpoint Inhibitors, Carcinoma, Hepatocellular, Humans, Immunotherapy, Liver Neoplasms, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.